Effect of PET‐CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long‐term results of a randomized controlled trial

2020 ◽  
Vol 121 (6) ◽  
pp. 1001-1006
Author(s):  
Pablo E. Serrano ◽  
Chu‐Shu Gu ◽  
Carol‐Anne Moulton ◽  
Mohamed Husien ◽  
Diederick Jalink ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomized Controlled Trial ◽  
Liver Metastases ◽  
Controlled Trial ◽  
Disease Recurrence ◽  
Long Term Results ◽  
Colorectal Cancer Liver Metastases ◽  
Randomized Controlled ◽  
Pet Ct

Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 562-562
Author(s):  
Pablo Emilio Serrano Aybar ◽  
Chu-Shu Gu ◽  
Mohamed Husien ◽  
Diederick Jalink ◽  
Guillaume Martel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Surgical Management ◽  
Disease Recurrence ◽  
Long Term Results ◽  
Colorectal Cancer Liver Metastases ◽  
Pet Ct ◽  
Risks Factors

562 Background: The PETCAM randomized trial evaluated the effect of preoperative PET-CT (vs. no PET-CT) on surgical management in patients with colorectal cancer liver metastases. In this study, 8% of patients had a change in surgical management, including a higher proportion of major liver resections in the PET-CT arm. The current study compares the intervention groups for 5-year disease free (DFS) and overall survival (OS), and evaluated their long-term clinical course, i.e. sites of recurrence and management of disease recurrence. Methods: Recruitment to the trial occurred between 2005-2010, with last follow-up in 2013. Data on recurrence, management of recurrence and mortality from 2013-2017 was collected from patient’s charts. Recurrences according to site and management were described. Cox proportional Hazard Models were used to calculate the risk for recurrence and death. OS was calculated with Kaplan-Meir method and compared with log-rank test. Results: At 5 years, 157 of 404 (39%) patients were still alive and 19 patients were lost to follow-up. Median follow-up is 4.2 years. There were no differences in DFS (HR: 1.12, 95%CI: 0.88-1.42) or OS (HR: 0.97, 95%CI: 0.74-1.28) between groups. The median DFS for the 372 patients who had surgery was 17 months, 95%CI: 14.7-19.4. Risks factors for recurrence were: extrahepatic disease, liver tumour size, and nodal stage. The median OS for all patients was 50 months, 95%CI: 43.5-64.3. Risks factors for death also included age and prior use of chemotherapy. During the follow-up period, 287/404, 71% patients recurred (mostly liver and lung); 137 (48%) were treated solely with chemotherapy and 35% were treated with surgery with curative intent. Of these, the majority recurred (109/116, 94%). The median OS following first recurrence was 27.5 months, 95%CI: 23-30. Conclusions: PET-CT did not improve DFS or OS. Survival following liver resection is similar to previous reports, however most patients experience disease recurrence. A substantial proportion of patients who recur undergo surgery, however it is likely that they will recur again.

A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: The UFT/LV study.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3584-3584 ◽  
Author(s):  
Akira Kobayashi ◽  
Kiyoshi Hasegawa ◽  
Akio Saiura ◽  
Tadatoshi Takayama ◽  
Shinichi Miyagawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomized Controlled Trial ◽  
Liver Metastases ◽  
Controlled Trial ◽  
Colorectal Cancer Liver Metastases ◽  
Randomized Controlled

scholarly journals Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial

PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0162400 ◽  
Author(s):  
Kiyoshi Hasegawa ◽  
Akio Saiura ◽  
Tadatoshi Takayama ◽  
Shinichi Miyagawa ◽  
Junji Yamamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Randomized Controlled Trial ◽  
Liver Metastases ◽  
Controlled Trial ◽  
Colorectal Cancer Liver Metastases ◽  
Randomized Controlled

ALPPS for Colorectal Cancer Liver Metastases—Short and Long-Term Results

2019 ◽  
pp. 469-486
Author(s):  
Kerollos Nashat Wanis ◽  
Bao Tram Nghiem ◽  
Roberto Hernandez-Alejandro
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Long Term Results ◽  
Colorectal Cancer Liver Metastases ◽  
Short And Long Term
Sign in / Sign up

Export Citation Format

Share Document